Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26587446 | 0.91 | FGFR2 (0.50) | BTKFGFR4FGFR1FGFR2ITK | |
| SCHEMBL30582523 | 0.91 | ITK (0.43) | BTKFGFR4FGFR1EGFRITK | |
| SCHEMBL26104650 | 0.91 | ITK (0.43) | BTKFGFR4FGFR1EGFRITK | |
| SCHEMBL26588835 | 0.90 | FGFR2 (0.39) | BTKFGFR4FGFR1EGFRFGFR2 | |
| SCHEMBL30582507 | 0.89 | BTK (0.43) | BTKFGFR4FGFR1EGFRITK | |
| SCHEMBL26587704 | 0.88 | FGFR4 (0.44) | BTKFGFR4FGFR1EGFRFGFR2 | |
| SCHEMBL30582513 | 0.88 | ITK (0.44) | BTKITK | |
| SCHEMBL30582525 | 0.88 | ITK (0.44) | BTKITK | |
| SCHEMBL26587541 | 0.88 | FGFR1 (0.47) | BTKFGFR4FGFR1EGFRFGFR2 | |
| SCHEMBL30582600 | 0.88 | SRC (0.44) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | claimed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |